ATE228004T1 - Verwendung von relaxin zur stimulierung der angiogenese - Google Patents

Verwendung von relaxin zur stimulierung der angiogenese

Info

Publication number: ATE228004T1
Authority: AT; Austria
Prior art keywords: relaxin; stimulate angiogenesis; angiogenesis; infections; lack
Prior art date: 1995-08-15

Application number

AT96928212T

Other languages

English (en)

Inventor

Elaine Unemori

Original Assignee

Connetics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-15

Filing date

1996-08-15

Publication date

2002-12-15

1996-08-15 Application filed by Connetics Corp filed Critical Connetics Corp

2002-12-15 Application granted granted Critical

2002-12-15 Publication of ATE228004T1 publication Critical patent/ATE228004T1/de

Links

102000003743 Relaxin Human genes 0.000 title abstract 2
108090000103 Relaxin Proteins 0.000 title abstract 2
230000033115 angiogenesis Effects 0.000 title abstract 2
208000027418 Wounds and injury Diseases 0.000 abstract 2
206010052428 Wound Diseases 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT96928212T 1995-08-15 1996-08-15 Verwendung von relaxin zur stimulierung der angiogenese ATE228004T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US235595P	1995-08-15	1995-08-15
PCT/US1996/013321 WO1997006814A1 (en)	1995-08-15	1996-08-15	Method of promoting angiogenesis

Publications (1)

Publication Number	Publication Date
ATE228004T1 true ATE228004T1 (de)	2002-12-15

Family

ID=21700396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96928212T ATE228004T1 (de)	1995-08-15	1996-08-15	Verwendung von relaxin zur stimulierung der angiogenese

Country Status (9)

Country	Link
US (3)	US6211147B1 (de)
EP (1)	EP0845992B1 (de)
JP (1)	JP4568383B2 (de)
AT (1)	ATE228004T1 (de)
AU (1)	AU6777196A (de)
CA (1)	CA2229479C (de)
DE (1)	DE69624925T2 (de)
ES (1)	ES2187667T3 (de)
WO (1)	WO1997006814A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE362770T1 (de) *	2000-02-09	2007-06-15	Bas Medical Inc	Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ITRM20020119A1 (it) *	2002-03-05	2003-09-05	Geymonat Spa	Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US7878978B2 (en)	2004-03-18	2011-02-01	University Of Pittsburgh- Of The Commonwealth System Of Higher Education	Use of relaxin to increase arterial compliance
AU2005223694B2 (en) *	2004-03-19	2011-04-28	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Use of relaxin to increase arterial compliance
AU2005247332A1 (en) *	2004-04-30	2005-12-08	Corthera, Inc.	Methods and compositions for control of fetal growth via modulation of relaxin
AU2006235489A1 (en) *	2005-04-12	2006-10-19	Intradigm Corporation	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US7893244B2 (en) *	2005-04-12	2011-02-22	Intradigm Corporation	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20060281669A1 (en) *	2005-06-13	2006-12-14	Yue Samuel K	Method and compositions for the treatment of diabetes and related complications
US8496446B2 (en) *	2005-08-29	2013-07-30	Carrier Corporation	Compressor muffler
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
EP2288367B1 (de) *	2008-05-16	2015-10-07	Corthera, Inc.	H2-Relaxin zur Verwendung bei der Behandlung von vorzeitiger Zervixdilatation
JP5651586B2 (ja)	2008-05-16	2015-01-14	コーセラ，インコーポレーテッド	急性心不全に伴う呼吸困難のリラキシンによる治療
US20100041603A1 (en) *	2008-05-16	2010-02-18	Corthera, Inc.	Method of Promoting Wound Healing
WO2010025530A1 (en) *	2008-09-05	2010-03-11	Universidade Federal Do Rio De Janeiro - Ufrj	Proteic acid polymer, production processes, use of proteic acid polymer, pharmaceutical composition and method of treatment
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
CA2737461A1 (en)	2008-09-19	2010-03-25	Tandem Diabetes Care, Inc.	Solute concentration measurement device and related methods
US20110152770A1 (en)	2009-07-30	2011-06-23	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP3572091B1 (de)	2010-08-17	2023-12-13	Ambrx, Inc.	Modifizierte relaxinpolypeptide und deren verwendungen
US10493131B2 (en) *	2011-08-31	2019-12-03	University Of Florida Research Foundation, Incorporated	Materials and methods for modulating activity of bone marrow derived cells
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
US9526762B1 (en) *	2013-08-09	2016-12-27	William Marsh Rice University	Multidomain peptides for promoting angiogenesis
PT3387019T (pt)	2015-12-09	2022-01-14	Scripps Research Inst	Proteínas de fusão de imunoglobulina de relaxina e métodos de uso

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5023321A (en) *	1982-12-13	1991-06-11	Howard Florey Institute Of Experimental Physiology & Medicine	Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5023088A (en) *	1987-06-25	1991-06-11	Alza Corporation	Multi-unit delivery system
AU626840B2 (en) *	1988-02-26	1992-08-13	Genentech Inc.	Human relaxin formulation
GB8907799D0 (en) *	1989-04-06	1989-05-17	Erba Carlo Spa	Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
CA2051375C (en)	1989-05-04	2000-09-12	Dennis J. Henner	Process and compositions for the isolation of human relaxin
US5194596A (en) *	1989-07-27	1993-03-16	California Biotechnology Inc.	Production of vascular endothelial cell growth factor
US5166191A (en)	1991-08-19	1992-11-24	Genentech, Inc.	Use of relaxin in cardiovascular therapy
US5478807A (en)	1991-08-19	1995-12-26	Genentech, Inc.	Use of relaxin in the treatment of bradycardia
WO1995003822A2 (en) *	1993-07-27	1995-02-09	Mario Bigazzi	Use of relaxin as therapeutic or preventing agent
US5911997A (en)	1995-06-07	1999-06-15	Connetics Corporation	Relaxin-like factor and methods and uses thereof
US5811395A (en) *	1995-06-07	1998-09-22	Medical University Of South Carolina	Relaxin analogs and derivatives methods and uses thereof
US5753623A (en) *	1995-06-07	1998-05-19	Connetics Corporation	Method of treatment for depression

1996
- 1996-08-15 CA CA2229479A patent/CA2229479C/en not_active Expired - Lifetime
- 1996-08-15 DE DE69624925T patent/DE69624925T2/de not_active Expired - Lifetime
- 1996-08-15 ES ES96928212T patent/ES2187667T3/es not_active Expired - Lifetime
- 1996-08-15 US US08/698,359 patent/US6211147B1/en not_active Expired - Lifetime
- 1996-08-15 EP EP96928212A patent/EP0845992B1/de not_active Expired - Lifetime
- 1996-08-15 WO PCT/US1996/013321 patent/WO1997006814A1/en not_active Ceased
- 1996-08-15 AT AT96928212T patent/ATE228004T1/de active
- 1996-08-15 AU AU67771/96A patent/AU6777196A/en not_active Abandoned
- 1996-08-15 JP JP50951597A patent/JP4568383B2/ja not_active Expired - Lifetime
2001
- 2001-02-08 US US09/780,758 patent/US6780836B2/en not_active Expired - Lifetime
2004
- 2004-04-05 US US10/818,859 patent/US20040192606A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0845992B1 (de)	2002-11-20
US20010018418A1 (en)	2001-08-30
US20040192606A1 (en)	2004-09-30
EP0845992A4 (de)	2000-04-19
CA2229479A1 (en)	1997-02-27
US6780836B2 (en)	2004-08-24
ES2187667T3 (es)	2003-06-16
DE69624925D1 (de)	2003-01-02
JP4568383B2 (ja)	2010-10-27
CA2229479C (en)	2010-03-30
WO1997006814A1 (en)	1997-02-27
AU6777196A (en)	1997-03-12
JPH11511174A (ja)	1999-09-28
US6211147B1 (en)	2001-04-03
EP0845992A1 (de)	1998-06-10
DE69624925T2 (de)	2003-09-04

Legal Events

Date

Code

Title

Description

2003-06-15

UEP

Publication of translation of european patent specification

Ref document number: 0845992

Country of ref document: EP

Publication	Publication Date	Title
DE69624925D1 (de)	2003-01-02	Verwendung von relaxin zur stimulierung der angiogenese
DE69034018D1 (de)	2002-12-19	Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE3855489D1 (de)	1996-09-26	Behandlung von Hautfalten
DE3687069D1 (de)	1992-12-10	Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
ES2038609T3 (es)	1993-08-01	4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
ATE113208T1 (de)	1994-11-15	Verwendung des wirkstoffs azelastin zur bekämpfung von psoriasis-erkrankungen.
ATE218862T1 (de)	2002-06-15	Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE3772513D1 (de)	1991-10-02	Behandlung von gewebe zur verbesserung seiner anfaerbbarkeit.
FI864570A0 (fi)	1986-11-11	Terapeutiskt anvaendbar foerening.
DE3884895D1 (de)	1993-11-18	Verwendung von Bezafibrat zur Behandlung von Diabetes.
DE3854121D1 (de)	1995-08-10	Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69634905D1 (de)	2005-08-04	Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung
ATE179594T1 (de)	1999-05-15	Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
ATE190486T1 (de)	2000-04-15	Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
ES2076141T3 (es)	1995-11-01	5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DE59808165D1 (de)	2003-06-05	Verwendung von aminothiazolen zur wund- und hautbehandlung
ATE109978T1 (de)	1994-09-15	Verwendung von purpuromycin zur behandlung von vaginalinfektionen.
ATE104142T1 (de)	1994-04-15	Verwendung von probucol zur praevention und behandlung von herzkrankheiten.
AT384624B (de)	1987-12-10	Einrichtung zur gesteuerten waermebehandlung von weichenteilen
ATE216884T1 (de)	2002-05-15	Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
IT8719277A0 (it)	1987-02-06	Capelli. composizione per il trattamento ela stimolazione della crescita dei
DE59410340D1 (de)	2004-01-15	Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE74755T1 (de)	1992-05-15	Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE69802828D1 (de)	2002-01-17	Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen
DE3881377D1 (de)	1993-07-01	Mittel zur prophylaxe und behandlung von thrombocytopenie.